II. CLAIM AMENDMENTS

Claims 1-12 (Cancelled, without prejudice or disclaimer)

13. (New) A method of treatment or prevention of menopausal complaints, comprising administering to a patient in need thereof an effective amount of a pharmaceutical formulation in the form of an immediate-release peroral dosage unit, comprising tibolone, wherein the pharmaceutical formulation has a biovailability, *in vivo*, of 3^{α}-OH tibolone at a level above that provided by a solution of tibolone, wherein the amount of tibolone in the immediate-release peroral dosage unit and in the tibolone solution are substantially the same.
14. (New) The method of Claim 13, wherein the tibolone in the immediate-release peroral dosage unit has a mean particle size below about 22.8 μm.
15. (New) The method of Claim 14, wherein the tibolone in the immediate-release peroral dosage unit has a mean particle size below about 20μm.
16. (New) The method of Claim 13, wherein the rate of dissolution of tibolone from the pharmaceutical formulation is such that when the pharmaceutical formulation is subjected to a dissolution-test, wherein a sample of said pharmaceutical formulation containing 2.5 mg of tibolone is exposed to a 0.25% sodium lauryl sulfate solution and the dissolution rate is measured, a $t_{50\%}$ value about 23.1 minutes is obtained.
17. (New) The method of Claim 16, wherein the tibolone in the immediate-release peroral dosage unit has a mean particle size below about 22.8 μm.